Sees FY25 Cell Engineering revenue $110M-$130M with potential upside from the recent launch of Tools offerings Ginkgo expects Biosecurity revenue in 2025 of at least $50M, representing approximate current contracted backlog and expected program renewal along with key assumption of continued availability of government funding, with potential upside from additional opportunities in the pipeline
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNA:
- Ginkgo Bioworks reports Q4 EPS ($2.00), consensus ($1.30)
- Ginkgo Bioworks options imply 17.6% move in share price post-earnings
- DNA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Ginkgo Bioworks integrates Callisto for NGS processes
- Ginkgo Bioworks partners with HaDEA in up to EUR 24M project